Study Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
Want to learn more about this trial?
Request More InfoInterventions
JY231 InjectionDRUG
The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Zhengzhou University | Zhenzhou | Henan | China |